Schematic diagram showing the structure and size of CytoSinct™ Nanobeads.
CytoSinct™ Cell Isolation kit including Nanobeads, Columns, and Magnetic Separator.
| GenScript CytoSinct™ |
Competitor A | Competitor B | Competitor C | |
|---|---|---|---|---|
|
Advanced Performance |
✓ | ✓ | ✓ | × |
|
Translational Research Compatibility |
✓ | ✓ | ✓ | × |
|
No Residual Beads on Cell Surface |
✓ | ✓ | ✓ | × |
|
No Bead-removal Step |
✓ | ✓ | × | ✓ |
|
Cost Efficiency |
✓ | × | × | ✓ |
GenScript's CytoSinct™ Nanobeads purify cells using a column-based separation method.
*These beads are compatible with magnetic columns for cell isolation from GenScript or another vendor.
High purity, recovery and viability of post-isolation cells
Figure 1. Purity, recovery and viability of CD4+ or CD8+ T-cells after isolation using CytoSinct™ Nanobeads.
3 different human PBMC samples were incubated with CytoSinct™ Nanobeads or a competitor product. CD4+ or CD8+ T-cells were then isolated using a column method and analyzed using flow cytometry. Pre- and post-isolation samples were stained with the cell viability dye 7-AAD and appropriate cell surface markers. CD4+ CD45+ cells or CD8+ CD45+ cells are gated from scatter/ singlets/ Live/. (A) Representative flow cytometry analyses. (B) High purity of post-isolation CD4+ or CD8+ T-cells using CytoSinct™ Nanobeads calculated as percentage of CD4+ or CD8+ T-cells in parent gating CD45+ 7AAD- from three different human PBMC samples. (C) High recovery of CD4+ or CD8+ T-cells using CytoSinct™ Nanobeads calculated as percentage of post-isolation CD4+ or CD8+ T-cells in total CD4+ or CD8+ T-cells in PBMC. (D) High viability of post-isolation CD4+ or CD8+ T-cells assessed by flow cytometry.
Isolated T-cells can be activated and expanded
Figure 2. Purified CD4+ or CD8+ T-cells shows high potential of activation and proliferation and high viability.
CD4+ or CD8+ T-cells are separated from 3 healthy donor PBMCs using GenScript CytoSinct™ Nanobeads or competitor product, subsequently cultured with supplemental IL-2, and activated for 3 days. (A) Representative flow cytometry analysis showing the activation biomarker of CD25 and CD69 expression on post-isolation CD4+ or CD8+ T-cells 72 hours after activation, (B) Cluster formation of post-isolation CD4+ or CD8+ T-cells 48 hours after activation. (C) Expansion curves of isolated CD4+ or CD8+ T-cells in culture. (D) Viability of CD4+ or CD8+ T-cells for 15 days after isolation.
Efficient cell isolation for translational research
Figure 3. Composition of cell subpopulations after CD4+ or CD8+ enrichment from a leukapheresis sample with GenScript CytoSinct™ Nanobeads or Competitor's magnetic beads at 10X higher concentration.
Purity and recovery are increased while percentage of non-target cells are decreased after separation with CytoSinct™ Nanobeads compared to competitor using magnetic column-based purification method (ns = non-significant).
Efficient depletion of unwanted cells
Figure 4. Flow cytometry analysis of negative fraction after CD4+ separation.
3 different human PBMC samples were processed for CD4 separation with GenScript's CytoSinct™ Nanobeads or a competitor product using a magnetic column-based purification method and analyzed using flow cytometry. Decrease in CD4+ T cell population was observed in negative fraction treated with CytoSinct™ Nanobeads compared to competitor product.
GenScript's Zhenjiang Biologics Manufacturing Center. Covering an area of 100,000 square meter space, the manufacturing center is designed and constructed in total compliance with the good manufacturing practice (GMP) requirements of FDA, EMEA and cFDA, and can meet the needs for Phase I to III clinical sample production and commercial production.
Efficient and gentle cell isolation based on surface markers is essential for researching specific cell populations, and for developing lifesaving cell and gene therapies. Purity, recovery and viability are among the most important characters of cells after isolation. CytoMagTM Nanobeads are nanometer-sized beads that isolate your target cells gently and efficiently, making your post-isolation cells suitable for a variety of down-stream applications. The separated cells are compatible with most downstream applications including cell culture, activation, expansion, flow cytometry analysis, and translational research.
• High Purity, Efficient Recovery, High Viability, High Specificity
Data: Leukopheresis samples were incubated with either GenScript’s CytoSinctTM CD3 Nanobeads or Competitor’s product, then isolated using column method and analyzed using flow cytometry.
Figure 1: Representative pre- and post-isolation data. Purity and recovery of CD3+ T-cells was analyzed after isolation using GenScript’s CytoMagTM CD3 Nanobeads or Competitor’s product.
Data: Human frozen PBMC samples were incubated with GenScript’s CytoSinctTM CD3 Nanobeads, isolated using column method, and analyzed using flow cytometry.
Figure 2: Representative pre- and post-isolation data using frozen PBMC as starting material. Purity, recovery, and viability of CD3+ T-cells was analyzed after isolation using GenScript’s CytoMagTM CD3 Nanobeads.
Efficient and gentle cell isolation based on surface markers is essential for researching specific cell populations, and for developing lifesaving cell and gene therapies. Purity, recovery and viability are among the most important characters of cells after isolation. CytoMagTM Nanobeads are nanometer-sized beads that isolate your target cells gently and efficiently, making your post-isolation cells suitable for a variety of down-stream applications. The separated cells are compatible with most downstream applications including cell culture, activation, expansion, flow cytometry analysis, and translational research.
• High Purity, Efficient Recovery, High Viability, High Specificity
CytoSinctTM CD4 Nanobeads shows comparable purity and recovery to Competitor’s product, as shown in Figures 1 and 2.
Data: Leukopheresis samples were incubated with either GenScript’s CytoSinctTM CD4 Nanobeads or Competitor’s product, then isolated using column method and analyzed using flow cytometry.
Figure 1: Representative pre- and post-isolation data. Purity and recovery of CD4+ T-cells was analyzed after isolation using GenScript’s CytoMagTM CD4 Nanobeads or Competitor’s product.
Data: Human frozen PBMC samples were incubated with GenScript’s CytoSinctTM CD4 Nanobeads, isolated using column method, and analyzed using flow cytometry.
Figure 2: Representative pre- and post-isolation data using frozen PBMC starting material. Purity, recovery, and viability of CD4+ T-cells was analyzed after isolation using GenScript’s CytoMagTM CD4 Nanobeads.
Efficient and gentle cell isolation based on surface markers is essential for researching specific cell populations, and for developing lifesaving cell and gene therapies. Purity, recovery and viability are among the most important characters of cells after isolation. CytoMagTM Nanobeads are nanometer-sized beads that isolate your target cells gently and efficiently, making your post-isolation cells suitable for a variety of down-stream applications. The separated cells are compatible with most downstream applications including cell culture, activation, expansion, flow cytometry analysis, and translational research.
• High Purity, Efficient Recovery, High Viability, High Specificity
Data: Leukopheresis samples were incubated with either GenScript’s CytoSinctTM CD8 Nanobeads or Competitor’s product, then isolated using column method and analyzed using flow cytometry.
Figure 1:Representative pre- and post-isolation data. Purity and recovery of CD8+ T-cells was analyzed after isolation using GenScript’s CytoMagTM CD8 Nanobeads or Competitor’s product.
Data:Human frozen PBMC samples were incubated with GenScript’s CytoSinctTM CD8 Nanobeads, isolated using column method, and analyzed using flow cytometry.
Figure 2: Representative pre- and post-isolation data using frozen PBMC as starting material. Purity, recovery, and viability of CD8+ T-cells was analyzed after isolation using GenScript’s CytoMagTM CD8 Nanobeads.
| Process | Product | Catalog Number | Description | Price |
|---|---|---|---|---|
| Automate | CytoSinct™ 1000 | D00023 | Compatible with all CytoSinct™ tubing set products | Quote |
| Manual | CytoSinct™ gStand | D00006 | Compatible with all CytoSinct™ Magnets | Quote |
| CytoSinct™ M1 magnet | D00009 | Holds 1 CytoSinct™ gM column | Quote | |
| CytoSinct™ M8 magnet | D00010 | Holds 8 CytoSinct™ gM columns | Quote | |
| CytoSinct™ L1 magnet | D00011 | Holds 1 CytoSinct™ gL column | Quote | |
| CytoSinct™ L4 magnet | D00012 | Holds 4 CytoSinct™ gL columns | Quote | |
| CytoSinct™ gM columns | D00007 | Up to 107 magnetically labeled cells from up to 2×108 total cells (each column) | Quote | |
| CytoSinct™ gL columns | D00008 | Up to 108 magnetically labeled cells from up to 2×109 total cells (each column) | Quote |
| Product | Catalog Number | Description | Price |
|---|---|---|---|
| CytoSinctTM 1000 Tubing Set, LS Tubing Set | D00029 | Up to 6×1010 total cells | Quote |
| D00030 | 1.2×1011 total cells | Quote | |
| CytoSinctTM 1000 Depletion Tubing Set | D00031 | Up to 1.2×1011 total cells | Quote |
| Application | Product | Catalog Number | Capacity | Package Size | Price |
|---|---|---|---|---|---|
|
T Cell
|
CytoSinct™ CD4 Nanobeads, human |
L00863
|
Up to 1X109 and 5X108 total MNCs | 0.5 ml1 ml | Quote |
| CytoSinct™ CD8 Nanobeads, human |
L00864
|
Up to 1X109 and 5X108 total MNCs | 0.5 ml1 ml | Quote | |
| CytoSinct™ CD3 Nanobeads, human |
L00896
|
Up to 1X109 and 5X108 total MNCs | 0.5 ml1 ml | Quote | |
| CytoSinct™ TCR αβ Nanobeads, human |
L00897coming
soon
|
Up to 1X109 and 5X108 total MNCs | 0.5 ml1 ml | Quote | |
|
Universal
|
CytoSinct™ Streptavidin Nanobeads |
L00898
|
Up to 1X109 and 5X108 total MNCs | 0.5 ml1 ml | Quote |
|
NK Cell
|
CytoSinct™ CD56 Nanobeads, human |
L00903
|
Up to 1X109 and 5X108 total MNCs | 0.5 ml1 ml | Quote |
|
Clinical
|
CytoSinct™ CD4, CD8 Nanobeads, human (GMP) |
L00932coming
soon
|
Up to 1.33X1010 and 4.00X1010 total MNCs | 2.5 ml | Quote |
| CytoSinct™ CD4, CD8 Nanobeads, human (GMP) |
L00933coming
soon
|
Up to 1.33X1010 and 4.00X1010 total MNCs | 7.5 ml | Quote | |
| CytoSinct™ CD3 Nanobeads, human (GMP) |
L00934coming
soon
|
Up to 4.00X1010 total MNCs | 7.5 ml | Quote |
| Application | Product | Catalog Number | Capacity | Package Size | Price |
|---|---|---|---|---|---|
|
Activation
|
Enceed™ T cell Activation, human |
L00899
|
Up to 2x108 and 1x108 T cells
|
0.5 ml1 ml | Quote |
|
Clinical Activation
|
Enceed™ T cell Activation, human (GMP) |
L00935coming soon
|
Up to 1.00X108 T cells
|
4 ml | Quote |
